ACM
PRLD icon

ADAR1 Capital Management’s Prelude Therapeutics PRLD Stock Holding History

ADAR1 Capital Management’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.8M Buy
900,900
+748,075
+489% +$3.26M 0.22% 104
2026
Q1 		$523K Buy
+152,825
New +$401K 0.03% 199

Other funds holding PRLD

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

ADAR1 Capital Management's PRLD Position: Q2 2026 in Review

ADAR1 Capital Management increased its Prelude Therapeutics (PRLD) stake by 489% in Q2 2026, buying an estimated $3.26M and bringing the position to 900,900 shares worth $4.8M. The position accounts for 0.22% of the portfolio, ranked #104.

ADAR1 Capital Management first reported a position in PRLD in Q1 2026 and has held it in 2 quarters since. 75 funds tracked by Wall St. Rank hold PRLD as of Q2 2026.

  • ADAR1 Capital Management held 900,900 shares of Prelude Therapeutics worth $4.8M as of Q2 2026.
  • ADAR1 Capital Management bought 748,075 Prelude Therapeutics shares in Q2 2026, an estimated $3.26M.
  • Prelude Therapeutics made up 0.22% of ADAR1 Capital Management's portfolio in Q2 2026, its #104 holding.
  • ADAR1 Capital Management first reported a position in Prelude Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 75 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q2 2026.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.